BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

March 12, 2024

https://www.globenewswire.com/news-release/2024/03/12/2844385/0/en/BioCardia-Announces-CMS-Approval-of-Coverage-for-CardiAMP-Cell-Therapy-Confirmatory-Phase-III-Heart-Failure-Study.html

SUNNYVALE, Calif., March 12, 2024 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced Centers for Medicare & Medicaid Services (CMS) approval for reimbursement coverage of the confirmatory Phase III clinical trial of CardiAMP autologous cell therapy for the treatment of patients with ischemic heart failure.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.